Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies
Marwa S. Asem(AbbVie (United States)), Jürgen Dinges(Abbott Fund), Fritz G. Buchanan(AbbVie (United States)), Yifei Kong(AbbVie (United States)), Milad Rouhimoghadam(University of Iowa), Anlu Chen(AbbVie (United States)), J.A. Ronau(AbbVie (United States)), Justin M. Reitsma(AbbVie (United States)), Stephanie Sandoval(AbbVie (United States)), Shaun McLoughlin(AbbVie (United States)), Sreenivas Punna(AbbVie (United States)), Peter Kovar(AbbVie (United States)), Colin Woodford(AbbVie (United States)), Yan Zhai(AbbVie (United States)), Andrea Shergalis(AbbVie (United States)), Daniel J. Cohen(AbbVie (United States)), Xiaohong Song(AbbVie (United States)), Yu Shen(AbbVie (United States)), Alla Korepanova(AbbVie (United States)), Ryan McClure(AbbVie (United States)), Vlasios Manaves(AbbVie (United States))
Cited by 1
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x <sub>L</sub> from NMR and Parallel Synthesis
|Journal of Medicinal Chemistry|2005|293
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
|Molecular Cancer Therapeutics|2016|185